Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies
Thao T. B. Cao,Kun-Chang Wu,Jye-Lin Hsu,Chih-Shiang Chang,Chiahung Chou,Chen-Yuan Lin,Yu-Min Liao,Pei-Chun Lin,Liang-Yo Yang,Hsiang-Wen Lin
DOI: https://doi.org/10.3389/fendo.2020.573891
IF: 6.055
2020-09-23
Frontiers in Endocrinology
Abstract:<span><strong>Background:</strong> As growing evidence links gut microbiota with the therapeutic efficacy and side effects of anti-hyperglycemic drugs, this article aims to provide a systematic review of the reciprocal interactions between anti-hyperglycemic drugs and gut microbiota taxa, which underlie the effect of the gut microbiome on diabetic control via bug-host interactions.<strong>Method:</strong> We followed the PRISMA requirements to perform a systematic review on human vs. animal gut microbiota data in PubMed, SCOPUS, and EMBASE databases, and used Cochrane, ROBIN-I, and SYRCLE tools to assess potential bias risks. The outcomes of assessment were trends on gut microbiota taxa, diversity, and associations with metabolic control (e.g., glucose, lipid) following anti-hyperglycemic treatment.<strong>Results:</strong> Of 2,804 citations, 64 studies (17/humans; 47/mice) were included. In human studies, seven were randomized trials using metformin or acarbose in obese, pre-diabetes, and type 2 diabetes (T2D) patients. Treatment of pre-diabetes and newly diagnosed T2D patients with metformin or acarbose was associated with decreases in genus of <i>Bacteroides</i>, accompanied by increases in both <i>Bifidobacterium</i> and <i>Lactobacillus</i>. Additionally, T2D patients receiving metformin showed increases in various taxa of the order <i>Enterobacteriales</i> and the species <i>Akkermansia muciniphila</i>. Of seven studies with significant differences in beta-diversity, the incremental specific taxa were associated with the improvement of glucose and lipid profiles. In mice, the effects of metformin on <i>A. muciniphila</i> were similar, but an inverse association with <i>Bacteroides</i> was reported. Animal studies on other anti-hyperglycemic drugs, however, showed substantial variations in results.<strong>Conclusions:</strong> The changes in specific taxa and β-diversity of gut microbiota were associated with metformin and acarbose in humans while pertinent information for other anti-hyperglycemic drugs could only be obtained in rodent studies. Further human studies on anti-hyperglycemic drugs other than metformin and acarbose are needed to explore gut microbiota's role in their therapeutic efficacies and side effects.</span>
endocrinology & metabolism